You are here

In Vivo Stem Cell Extraction Device

Award Information
Agency: Department of Defense
Branch: Army
Contract: W81XWH-10-C-0035
Agency Tracking Number: A2-4647
Amount: $727,246.00
Phase: Phase II
Program: SBIR
Solicitation Topic Code: A09-154
Solicitation Number: 2009.3
Timeline
Solicitation Year: 2009
Award Year: 2011
Award Start Date (Proposal Award Date): 2012-01-15
Award End Date (Contract End Date): N/A
Small Business Information
15 Schoen Place
Pittsford, NY -
United States
DUNS: 002587730
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Christopher Strohsahl
 Director of Development
 (585) 355-1292
 cstrohsahl@celltraffix.com
Business Contact
 Thomas Fitzgerald
Title: CEO
Phone: (585) 267-4840
Email: tfitzgerald@celltraffix.com
Research Institution
 Stub
Abstract

The need for controlled medical tissue regeneration in trauma or disease therapies has long existed. Only recently, however, has sufficient technology been developed to even begin exploring human applications. A key breakthrough was the discovery of the stem cell as a significant element for regeneration. Previous work has suggested that stem cells can be targeted and captured in a synthetic microfluidic system that mimics the molecular cell-adhesion mechanisms used by the body for physiological trafficking in the microcirculation. The scope of this project is to initiate a plan to translate this discovery towards the development of a microfluidic cell capture device (the CellSelect System) that is capable of capturing sufficient numbers of stem cells for practical regenerative biomedical applications. The objectives of this project are to further advance the optimization efforts that were initiated during Phase I of the research product as well as complete the design, development and pre-clinical testing of the initial prototypes that will be introduced to the market during Phase III. Additionally, during the course of the Phase II research, we will demonstrate that the stem cells captured using this technology possess superior engrafting capabilities, thus making them ideal candidates for use in regenerative medicine.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government